BF-A vs JBS

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. Despite solid profitability metrics like a 29.44% operating margin and 20.67% ROE, the company faces significant headwinds with negative revenue and earnings growth. Valuation appears stretched relative to intrinsic value models, and insider selling, weak price performance, and declining fundamentals reinforce caution. The stock trades well above the Graham Number of $18.3, suggesting overvaluation absent exceptional growth—contradicted by current contraction trends.

JBS presents as a classic value play with a Piotroski F-Score of 4/9, indicating stable but not robust financial health. The stock currently trades at a discount to its Graham Number ($18.61) and offers a highly attractive 8.31% dividend yield supported by a very low payout ratio. While revenue growth remains strong at 15.5%, the decline in earnings growth and a high debt-to-equity ratio (2.52) are the primary headwinds. The strong ROE of 25.26% and a 'strong_buy' analyst consensus suggest significant upside potential despite current bearish technical trends.